Genertec Universal Medical Group SEHK:2666 Stock Report
Last Price
HK$4.89
Market Cap
HK$9.2b
7D
1.5%
1Y
-27.1%
Updated
22 May, 2022
Data
Company Financials +
2666 fundamental analysis
Snowflake Score
Valuation
5/6
Future Growth
1/6
Past Performance
2/6
Financial Health
3/6
Dividends
2/6
2666 Stock Overview
Genertec Universal Medical Group Company Limited, together with its subsidiaries, offers financing and advisory services in the People’s Republic of China.
Genertec Universal Medical Group Company Limited, together with its subsidiaries, offers financing and advisory services in the People’s Republic of China. It operates in two segments, Finance and Advisory and Hospital Group. The Finance and Advisory segment provides direct finance leasing; sale and leaseback; factoring; operating leases; and advisory services.
Genertec Universal Medical Group Fundamentals Summary
How do Genertec Universal Medical Group's earnings and revenue compare to its market cap?
Is Genertec Universal Medical Group undervalued compared to its fair value and its price relative to the market?
Valuation Score
5/6
Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
40.0%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 2666 (HK$4.89) is trading below our estimate of fair value (HK$8.15)
Significantly Below Fair Value: 2666 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 2666 is good value based on its PE Ratio (4.3x) compared to the Hong Kong Diversified Financial industry average (8.8x).
PE vs Market: 2666 is good value based on its PE Ratio (4.3x) compared to the Hong Kong market (8.8x).
Price to Earnings Growth Ratio
PEG Ratio: 2666 is good value based on its PEG Ratio (0.3x)
Price to Book Ratio
PB vs Industry: 2666's PB Ratio (0.5x) is in line with the HK Diversified Financial industry average.
Future Growth
How is Genertec Universal Medical Group forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score
1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
16.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2666's forecast earnings growth (16.1% per year) is above the savings rate (1.5%).
Earnings vs Market: 2666's earnings (16.1% per year) are forecast to grow slower than the Hong Kong market (16.6% per year).
High Growth Earnings: 2666's earnings are forecast to grow, but not significantly.
Revenue vs Market: Insufficient data to determine if 2666's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 2666's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2666's Return on Equity is forecast to be low in 3 years time (16.7%).
Past Performance
How has Genertec Universal Medical Group performed over the past 5 years?
Past Performance Score
2/6
Past Performance Score 2/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
13.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2666 has high quality earnings.
Growing Profit Margin: 2666's current net profit margins (19.2%) are lower than last year (20%).
Past Earnings Growth Analysis
Earnings Trend: 2666's earnings have grown by 13% per year over the past 5 years.
Accelerating Growth: 2666's earnings growth over the past year (11.4%) is below its 5-year average (13% per year).
Earnings vs Industry: 2666 earnings growth over the past year (11.4%) underperformed the Diversified Financial industry 20.9%.
Return on Equity
High ROE: 2666's Return on Equity (11.5%) is considered low.
Financial Health
How is Genertec Universal Medical Group's financial position?
Financial Health Score
3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: 2666's short term assets (CN¥64.5B) exceed its short term liabilities (CN¥18.7B).
Long Term Liabilities: 2666's short term assets (CN¥64.5B) exceed its long term liabilities (CN¥33.5B).
Debt to Equity History and Analysis
Debt Level: 2666's net debt to equity ratio (229.7%) is considered high.
Reducing Debt: 2666's debt to equity ratio has reduced from 283.1% to 243% over the past 5 years.
Debt Coverage: 2666's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if 2666's interest payments on its debt are well covered by EBIT.
Balance Sheet
Dividend
What is Genertec Universal Medical Group current dividend yield, its reliability and sustainability?
Dividend Score
2/6
Dividend Score 2/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
7.07%
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 2666's dividend (7.07%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.84%).
High Dividend: 2666's dividend (7.07%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.83%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 2666 has been paying a dividend for less than 10 years.
Growing Dividend: 2666's dividend payments have increased, but the company has only paid a dividend for 6 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (29.7%), 2666's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: 2666 is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
5.3yrs
Average management tenure
CEO
Wang Wenbing (47 yo)
5.25yrs
Tenure
CN¥1,629,000
Compensation
Mr. Wang Wenbing has been Deputy General Manager of Genertec Universal Medical Group Company Limited (formerly known as Universal Medical Financial & Technical Advisory Services Company Limited) since Febr...
CEO Compensation Analysis
Compensation vs Market: Wang's total compensation ($USD243.39K) is below average for companies of similar size in the Hong Kong market ($USD556.26K).
Compensation vs Earnings: Insufficient data to compare Wang's compensation with company performance.
Leadership Team
Experienced Management: 2666's management team is seasoned and experienced (5.3 years average tenure).
Board Members
Experienced Board: 2666's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 2666 insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Genertec Universal Medical Group Company Limited's employee growth, exchange listings and data sources
Key Information
Name: Genertec Universal Medical Group Company Limited
All financial data provided by Standard & Poor's Capital IQ.
Data
Last Updated (UTC time)
Company Analysis
2022/05/22 00:00
End of Day Share Price
2022/05/20 00:00
Earnings
2021/12/31
Annual Earnings
2021/12/31
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.